• Molecular NameZidovudine
  • SynonymNA
  • Weight266.237
  • Drugbank_IDDB00495
  • ACS_NO30516-87-1
  • Show 2D model
  • LogP (experiment)0.05
  • LogP (predicted, AB/LogP v2.0)-0.07
  • pkaN/A
  • LogD (pH=7, predicted)-0.07
  • Solubility (experiment)24.9 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-1.86
  • LogSw (predicted, AB/LogsW2.0)16.7
  • Sw (mg/ml) (predicted, ACD/Labs)3.7
  • No.of HBond Donors2
  • No.of HBond Acceptors9
  • No.of Rotatable Bonds3
  • TPSA109.19
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA nucleoside analog reverse transcriptase inhibitor (NRTI), a type of antiretroviral drug. It was the first approved treatment for HIV.
  • Absorption_value96.0
  • Absorption (description)N/A
  • Caco_2-5.16
  • Bioavailability63.0
  • Protein binding25.0
  • Volume of distribution (VD)1.4 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMetabolized by glucuronide conjugation to major, inactive metabolite, 3'-azido-3'-deoxy-5'- O-beta-D-glucopyranuronosylthymidine (GZDV).
  • Half life1.1 h
  • ExcretionRenal
  • Urinary Excretion18
  • Clerance26 ml/min/kg
  • ToxicitySymptoms of overdose include fatigue, headache, nausea, and vomiting. LD50 is 3084 mg/kg (orally in mice).
  • LD50 (rat)N/A
  • LD50 (mouse)N/A